Theriva Biologics Statistics
Share Statistics
Theriva Biologics has 2.78M shares outstanding. The number of shares has increased by -92.06% in one year.
| Shares Outstanding | 2.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -92.16% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.75M |
| Failed to Deliver (FTD) Shares | 5.21K |
| FTD / Avg. Volume | 0.18% |
Short Selling Information
The latest short interest is 90.95K, so 3.27% of the outstanding shares have been sold short.
| Short Interest | 90.95K |
| Short % of Shares Out | 3.27% |
| Short % of Float | 3.31% |
| Short Ratio (days to cover) | 0.03 |
Valuation Ratios
The PE ratio is -0.38 and the forward PE ratio is -0.08.
| PE Ratio | -0.38 |
| Forward PE | -0.08 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.17 |
| P/FCF Ratio | -0.36 |
| PEG Ratio | n/a |
Enterprise Valuation
Theriva Biologics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.07, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.07 |
| Quick Ratio | 4.07 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.76 |
| Cash Flow / Debt | -26.68 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.46% and return on capital (ROIC) is -47.01%.
| Return on Equity (ROE) | -0.46% |
| Return on Assets (ROA) | -0.33% |
| Return on Capital (ROIC) | -47.01% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -834.05K |
| Employee Count | 22 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1.64M |
| Effective Tax Rate | 0.08 |
Stock Price Statistics
The stock price has increased by -91.79% in the last 52 weeks. The beta is 1.34, so Theriva Biologics 's price volatility has been higher than the market average.
| Beta | 1.34 |
| 52-Week Price Change | -91.79% |
| 50-Day Moving Average | 1.48 |
| 200-Day Moving Average | 5.9 |
| Relative Strength Index (RSI) | 37.56 |
| Average Volume (20 Days) | 2.92M |
Income Statement
In the last 12 months, Theriva Biologics had revenue of $0 and earned -$18.35M in profits. Earnings per share was $-28.49.
| Revenue | 0 |
| Gross Profit | -135.00K |
| Operating Income | -21.43M |
| Net Income | -18.35M |
| EBITDA | -19.85M |
| EBIT | - |
| Earnings Per Share (EPS) | -28.49 |
Balance Sheet
The company has $23.18M in cash and $2.15M in debt, giving a net cash position of $21.02M.
| Cash & Cash Equivalents | 23.18M |
| Total Debt | 2.15M |
| Net Cash | 21.02M |
| Retained Earnings | -309.32M |
| Total Assets | 40.11M |
| Working Capital | 12.21M |
Cash Flow
In the last 12 months, operating cash flow was -$19.00M and capital expenditures -$202.00K, giving a free cash flow of -$19.20M.
| Operating Cash Flow | -19.00M |
| Capital Expenditures | -202.00K |
| Free Cash Flow | -19.20M |
| FCF Per Share | -29.81 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
TOVX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2435.04% |
| FCF Yield | -592.25% |
Analyst Forecast
The average price target for TOVX is $6, which is 412.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 412.8% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 26, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Aug 26, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -12.76 |
| Piotroski F-Score | 3 |